Pork Tapeworm Infection Treatment Market

Pork Tapeworm Infection Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Pork Tapeworm Infection Treatment Market

• Demand and Growth Drivers
  • Expansion of neuroimaging capabilities in endemic regions is expected to increase neurocysticercosis case identification rates, converting previously undiagnosed patients into active treatment demand.
  • WHO-coordinated mass deworming programs are expected to sustain baseline procurement volumes for praziquantel and albendazole through government and NGO distribution channels.
  • Growing awareness of food safety risks and improved diagnostic access are expected to increase treatment volumes across both endemic and non-endemic market settings.
• Product and Segment View
  • Praziquantel is expected to lead the drug type segment with 45.9% share in 2026, reflecting its position as the WHO-recommended first-line treatment for taeniasis and neurocysticercosis.
  • CT scans are expected to represent 52.3% of the treatment segment, driven by cost-effective neuroimaging for cyst detection and treatment monitoring.
  • Hospitals and laboratories are expected to account for 46.9% of end-user demand, supported by centralized diagnostic and treatment capabilities.
• Geography and Competitive Outlook
  • South Korea (7.9%) is expected to lead growth, supported by food safety investment and expanded screening protocols.
  • The EU (7.5%) and the USA (7.4%) represent strong growth markets driven by immigrant health programs and travel medicine diagnostics.
  • Companies with WHO-prequalified manufacturing and established government procurement relationships are expected to maintain supply chain advantages.
• Analyst Opinion
  • The pork tapeworm infection treatment market is evolving from a mass deworming-focused procurement category into a more diagnostically driven treatment market as neuroimaging access expands.
  • Adoption of combination treatment protocols is increasing per-patient treatment value while improving clinical outcomes in neurocysticercosis management.
  • The market is benefiting from expanded One Health initiatives that integrate human treatment programs with livestock vaccination and food safety surveillance.
  • Companies that can maintain WHO-prequalified manufacturing while developing improved formulations, including pediatric oral suspensions and extended-release combinations, are expected to strengthen market positions over the forecast period.

Key Takeaways, Market Size, and Forecast

• The pork tapeworm infection treatment market was valued at USD 13.60 billion in 2025.
• By 2036, the Pork Tapeworm Infection Treatment Market is expected to be worth USD 30.76 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 7.7%.
• The market is projected to create an incremental opportunity of USD 16.11 billion between 2026 and 2036.
• In 2026, praziquantel is expected to account for 45.9% of the drug type segment, driven by established first-line prescribing patterns and WHO-recommended treatment protocols for taeniasis and neurocysticercosis.
• South Korea (7.9%) and EU (7.5%) are two of the fastest growing markets in the world.

Pork Tapeworm Infection Treatment Market Definition

The pork tapeworm infection treatment market covers therapeutic products used in the management of Taenia solium infections, including taeniasis and neurocysticercosis. Products include anthelmintic drugs such as praziquantel and albendazole, diagnostic imaging services, and supportive care pharmaceuticals distributed through hospital, retail, and online pharmacy channels.

Pork Tapeworm Infection Treatment Market Inclusions

Market scope covers all commercially available pork tapeworm infection treatments categorized by drug type (praziquantel, albendazole, nitazoxanide, others), treatment (CT scan, MRI, ultrasound, X-ray), end user (hospitals and laboratories, specialty clinics, ambulatory surgical centres, others), and distribution channel (hospital pharmacies, retail pharmacies, online pharmacies). Revenue coverage spans 2026 to 2036.

Pork Tapeworm Infection Treatment Market Exclusions

The scope does not include veterinary anthelmintic products used exclusively in swine health, public sanitation infrastructure investments, or meat inspection equipment.

Pork Tapeworm Infection Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with parasitologists, infectious disease specialists, and pharmaceutical procurement managers at national deworming program agencies across key markets.
• Desk Research: Combined data from WHO neglected tropical disease reports, national deworming program procurement records, and pharmaceutical distribution databases.
• Market Sizing and Forecasting: Bottom-up sizing across drug type, treatment modality, and distribution channel segments with regional prevalence and treatment access curves.
• Data Validation: Cross-checked quarterly against WHO disease surveillance data, government pharmaceutical procurement records, and manufacturer shipment volumes.

Why is the Pork Tapeworm Infection Treatment Market Growing?

• Rising diagnostic capabilities for neurocysticercosis, particularly through expanded CT and MRI access in endemic regions, are increasing the identified patient population and corresponding treatment demand.
• WHO-coordinated mass deworming programs in Latin America, Sub-Saharan Africa, and South and Southeast Asia are sustaining procurement volumes for praziquantel and albendazole through government and NGO channels.
• Growing awareness of food safety risks associated with pork consumption in endemic areas is increasing demand for both preventive deworming and acute treatment interventions across public health systems.

Demand for pork tapeworm infection treatment reflects a convergence of improved diagnostic access and sustained public health intervention programs. Neurocysticercosis, the most severe manifestation of Taenia solium infection, accounts for a significant proportion of epilepsy cases in endemic regions. The expansion of neuroimaging capabilities in secondary and tertiary care facilities across Latin America and South Asia is increasing case identification rates, converting previously undiagnosed patients into active treatment demand.

Adoption of combination treatment protocols is increasing as clinical evidence supports the use of praziquantel with corticosteroids and anticonvulsants for neurocysticercosis management. This multi-drug approach improves treatment outcomes but also increases per-patient pharmaceutical expenditure, contributing to overall market value growth beyond simple volume increases.

Pricing remains influenced by the generic-dominated product mix, with praziquantel and albendazole available at low cost through WHO prequalified manufacturers. Government procurement through mass drug administration programs represents the primary distribution mechanism in endemic regions, while retail and online pharmacy channels serve diagnosed patients in non-endemic markets where imported cases are managed through travel medicine and infectious disease clinics.

Market Segmentation Analysis

• Praziquantel accounts for 45.9% of the drug type segment, reflecting established demand patterns across primary application areas.
• CT Scan represents 52.3% of the treatment segment, supported by institutional procurement structures.
• Hospitals & Laboratories leads the end user segment with 46.9% share, driven by volume-based procurement in clinical environments.

The pork tapeworm infection treatment market is segmented by drug type, treatment, end user, and distribution channel.

Insights into the Praziquantel Drug Type Segment

Praziquantel maintains its position as the first-line anthelmintic for both intestinal taeniasis and neurocysticercosis. Its oral formulation, favorable safety profile, and inclusion in WHO essential medicines lists ensure consistent procurement through government health programs and mass drug administration campaigns.

Insights into the CT Scan Treatment Segment

CT scans represent the primary diagnostic modality for neurocysticercosis, enabling identification of cyst location, number, and developmental stage. The cost-effectiveness and widespread availability of CT imaging relative to MRI supports its dominant position in both urban tertiary centres and increasingly in regional diagnostic facilities.

Pork Tapeworm Infection Treatment Market Drivers, Restraints, and Opportunities

• Regulatory and structural demand drivers are creating sustained procurement patterns across established and emerging markets.
• Cost and access constraints create segmentation in adoption rates across healthcare systems with varying budget frameworks.
• Technology and product development are expanding treatment options and creating new market segments.

The pork tapeworm infection treatment market is shaped by regulatory requirements, technology evolution, and shifting procurement structures.

Expanded Neuroimaging Access in Endemic Regions

Growth reflects the expansion of CT and MRI diagnostic capabilities in secondary care facilities across endemic regions. Increased case identification of neurocysticercosis converts undiagnosed patients into active treatment demand, driving pharmaceutical procurement volumes beyond baseline mass deworming program levels.

WHO Mass Deworming Program Sustainability

Demand is shaped by recurring government and NGO procurement for mass drug administration programs targeting soil-transmitted helminths and taeniasis. These programs provide volume stability for generic anthelmintic manufacturers and sustain distribution infrastructure in endemic regions.

Combination Treatment Protocol Adoption

Adoption of multi-drug treatment approaches for neurocysticercosis, combining praziquantel with corticosteroids and anticonvulsants, is increasing per-patient treatment value while improving clinical outcomes in complicated cases.

Limited Treatment Innovation Pipeline

The generic-dominated product landscape and limited commercial incentives for new drug development constrain innovation in the treatment category. Neglected tropical disease funding mechanisms and public-private partnerships partially address this gap.

Analysis of Pork Tapeworm Infection Treatment Market By Key Countries

Country	CAGR
South Korea	7.9%
EU	7.5%
USA	7.4%
UK	7.1%
Japan	7.0%

• South Korea leads with 7.9% CAGR, supported by established infrastructure and investment programs.
• EU at 7.5% reflects expanding capabilities and modernization investment.
• USA (7.4%) and UK (7.1%) maintain growth through institutional frameworks.

The global pork tapeworm infection treatment market is expected to grow at a rate of 7.7% per year from 2026 to 2036. The study covers more than 30 countries.

Future Outlook for Pork Tapeworm Infection Treatment Market in South Korea

South Korea is expected to grow at 7.9% through 2036. Investment in food safety surveillance, expanded screening protocols for imported cases, and growing awareness of neurocysticercosis management are supporting steady growth.

• Food safety inspection programs increase case identification rates.
• Participation in multinational clinical trials expands treatment protocol options.
• Government health screening initiatives support diagnostic accessibility.

Opportunity Analysis of Pork Tapeworm Infection Treatment Market in the European Union

The EU is expected to grow at 7.5% through 2036. Harmonized parasitic disease control programs, accessibility to anthelmintic treatments, and EU-funded neglected tropical disease research support consistent demand.

• Harmonized EU health programs standardize treatment access across member states.
• Immigrant health screening programs increase diagnosed case volumes.
• EU research funding supports new antiparasitic drug development.

Demand Outlook for Pork Tapeworm Infection Treatment Market in the United States

The USA is expected to grow at 7.4% through 2036, supported by improving diagnostic capabilities, public health surveillance of imported cases, and clinical research into neurocysticercosis management.

• Travel medicine and immigration screening programs identify imported cases.
• Neuroimaging accessibility supports neurocysticercosis diagnosis.
• Clinical research programs advance combination treatment protocols.

In-depth Analysis of Pork Tapeworm Infection Treatment Market in the United Kingdom

The UK is expected to grow at 7.1% through 2036, supported by NHS diagnostic infrastructure and international travel-related case management in infectious disease clinics.

• NHS infectious disease clinics manage travel-related tapeworm infections.
• Improved diagnostic protocols support timely case identification.
• Government food safety standards reduce domestic transmission risk.

Sales Analysis of Pork Tapeworm Infection Treatment Market in Japan

Japan is expected to grow at 7.0% through 2036. Advanced diagnostic infrastructure, food safety screening, and WHO-aligned treatment protocols support market development.

• Advanced diagnostic infrastructure supports rapid case identification.
• Food import screening programs monitor parasitic contamination risks.
• Neurology-focused treatment centres manage neurocysticercosis cases.

Competitive Landscape and Strategic Positioning

• Merck & Co., Inc. leads with an estimated 20.0% market share.
• The competitive landscape includes global manufacturers with broad portfolios and specialized players.
• Entry barriers include regulatory requirements, established relationships, and scale-dependent advantages.

Merck & Co., Inc. leads the market through its established position in antiparasitic drug access and global health initiative partnerships that support low-cost distribution of praziquantel through WHO-coordinated programs.

Pfizer Inc. and GlaxoSmithKline plc maintain positions through clinical-grade anthelmintic formulations and large-scale global health delivery models that supply neglected tropical disease-targeted therapies through WHO and NGO networks.

Cipla Ltd. and Lupin Pharmaceuticals, Inc. compete on cost-effective generic formulations designed for low- and middle-income country markets, offering bundled therapies and pediatric-friendly delivery systems.

Entry barriers are low in terms of generic drug manufacturing but significant in terms of securing WHO prequalification, government procurement contracts, and integration into established mass drug administration supply chains.

Key Companies in the Pork Tapeworm Infection Treatment Market

Key global companies leading the pork tapeworm infection treatment market include:

• Merck & Co., Inc. (USA), Pfizer Inc. (USA), and GlaxoSmithKline plc (UK) hold leading positions through established global health partnerships, WHO-coordinated distribution, and broad anthelmintic portfolios.
• Cipla Ltd. (India) and Lupin Pharmaceuticals, Inc. (India) compete on affordable generic formulations targeting mass drug administration programs in endemic regions.
• Strides Pharma Science Limited (India), Aurobindo Pharma (India), and Shin Poong Pharmaceutical Co., Ltd. (South Korea) represent emerging positions through WHO-prequalified generic manufacturing and regional procurement partnerships.

Competitive Benchmarking: Pork Tapeworm Infection Treatment Market

Company	Drug Portfolio	Global Health Access	Manufacturing Scale	Geographic Reach
Merck & Co., Inc.	High	Strong	High	Global
Pfizer Inc.	High	Strong	High	Global
Cipla Ltd.	Medium	Strong	High	Asia, Africa
GlaxoSmithKline plc	Medium	Strong	High	Global
Lupin Pharmaceuticals, Inc.	Medium	Moderate	Medium	Asia, Africa
Strides Pharma Science Limited	Low	Moderate	Medium	Asia
Aurobindo Pharma	Low	Moderate	High	Asia, Global
Shin Poong Pharmaceutical	Low	Moderate	Medium	Asia
Medopharm	Low	Low	Low	India
Ajanta Pharma Ltd.	Low	Low	Medium	Asia, Africa

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Pork Tapeworm Infection Treatment Market

• In 2025, Cipla continued to supply standard generic drugs used in established treatments for pork tapeworm infection, rather than introducing a new combination product.
• In 2025, Merck KGaA maintained its long-standing partnership with the WHO to supply praziquantel for the elimination of schistosomiasis—a different parasitic disease—rather than pork tapeworm.

Key Players in the Pork Tapeworm Infection Treatment Market

Major Global Players

• Merck & Co., Inc.
• Pfizer Inc.
• Cipla Ltd.
• GlaxoSmithKline plc
• Lupin Pharmaceuticals, Inc.
• Strides Pharma Science Limited
• Aurobindo Pharma

Emerging Players/Startups

• Strides Pharma Science Limited
• Aurobindo Pharma
• Shin Poong Pharmaceutical Co., Ltd.
• Medopharm
• Ajanta Pharma Ltd.

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 14.65 billion to USD 30.76 billion, at a CAGR of 7.7%
Market Definition	The pork tapeworm infection treatment market covers therapeutic products used in the management of Taenia solium infections, including taeniasis and neurocysticercosis. Products include anthelmintic drugs such as praziquantel and albendazole, diagnostic imaging services, and supportive care pharmaceuticals distributed through hospital, retail, and online pharmacy channels.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled	Merck & Co., Inc., Pfizer Inc., Cipla Ltd., GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Strides Pharma Science Limited, Aurobindo Pharma, Shin Poong Pharmaceutical Co., Ltd., Medopharm, Ajanta Pharma Ltd.
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Pork Tapeworm Infection Treatment Market Segmented by Drug Type:

• Praziquantel
• Albendazole
• Nitazoxanide
• Others

Pork Tapeworm Infection Treatment Market Segmented by Treatment:

• CT Scan
• MRI
• Ultrasound
• X-Ray

Pork Tapeworm Infection Treatment Market Segmented by End User:

• Hospitals & Laboratories
• Specialty Clinics
• Ambulatory Surgical Centres
• Others

Pork Tapeworm Infection Treatment Market Segmented by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Pork Tapeworm Infection Treatment Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO Guidelines on Control of Taenia solium and Prevention of Neurocysticercosis. WHO.
• 2. USA Centers for Disease Control and Prevention. (2024). CDC Parasitic Disease Surveillance: Taeniasis and Cysticercosis. CDC.
• 3. Food and Agriculture Organization. (2025). FAO Food Safety Guidelines: Pork Inspection Standards. FAO.
• 4. Pan American Health Organization. (2024). PAHO Neglected Tropical Disease Control Programs: Latin America. PAHO.
• 5. World Bank. (2025). World Bank Health, Nutrition and Population Data: Neglected Tropical Disease Investment. World Bank.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the market size and revenue from 2026 to 2036.
• Segmentation by drug type, treatment, end user, and distribution channel.
• Regional and country-level insights across more than 30 markets.
• Diagnostic technology analysis covering CT, MRI, ultrasound, and X-ray modalities.
• Competitive landscape assessment.
• Investment opportunity identification in endemic and non-endemic market segments.
• Supply chain and distribution channel analysis.
• Data delivery in PDF and Excel formats.